RISA Labs Nets $11M for US Cancer AI Expansion
Overview
Healthcare AI firm RISA Labs secured $11.1 million in Series A funding, co-led by Cencora Ventures and Optum Ventures. The capital will propel the distribution of its AI-powered oncology workflow system, BOSS, across U.S. cancer clinics and health systems. RISA claims its AI significantly cuts administrative time and improves approval rates, addressing critical pain points in cancer care.
AI Startup RISA Labs Secures $11.1 Million to Enhance Cancer Care Workflows
US-based RISA Labs has raised $11.1 million (over INR 100 crore) in a Series A funding round, co-led by Cencora Ventures and Optum Ventures. The capital infusion will accelerate the deployment of RISA's artificial intelligence-powered system designed to streamline complex oncology workflows within cancer clinics and health systems across the United States.
The company's flagship AI console, BOSS, simplifies intricate oncology processes into manageable tasks executed by AI agents. This system is specifically engineered for cancer care, capable of navigating complex payer rules, multi-drug regimens, and disease-specific requirements. Founded in June 2024 by Kshitij Jaggi and Kumar Shivang, RISA Labs aims to solve critical mathematical challenges inherent in modern cancer treatment.
RISA Labs reports significant operational improvements at early-adopting U.S. oncology practices. The startup claims its AI has freed up approximately 80% of administrative staff time, reduced claim denials by up to 40%, and achieved a 97.8% first-pass approval rate. These metrics highlight the potential for AI to drive efficiency and cost savings in a high-stakes medical field.
The investment arrives amid heightened investor interest in the healthcare sector, particularly in AI integration. The technology promises greater accuracy in medical diagnostics and a faster timeline for treatment and diagnosis compared to manual methods. This funding round positions RISA Labs for deeper expansion within oncology in 2026, focusing on partnerships to cover the full spectrum of cancer care.
